Physician profile
Bryan K Dunn
NPI 1972739811
$12,277.28
in general payments reported to CMS, 2019-2025
27 companies · $6,069 in 2025
The $6,069 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,628 · 2020: $1,290 · 2022: $330 · 2023: $381 · 2024: $579 · 2025: $6,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,978 · Travel and Lodging: $1,546 · Food and Beverage: $1,473 · Grant: $32.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,978.00 |
| Travel and Lodging | $1,545.80 |
| Food and Beverage | $1,473.30 |
| Grant | $32.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,786.21 | 2025 | |
| Covidien LP | $2,451.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,729.44 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Medtronic, INC. | $1,713.00 | 2023-2025 | Illumisite |
| Olympus Corporation of The Americas | $1,074.66 | 2019-2020 | |
| Glaxosmithkline, LLC. | $391.94 | 2019-2024 | Arexvy, Nucala |
| Genentech USA, INC. | $154.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $132.05 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Amgen INC. | $123.37 | 2022 | |
| Allergan, INC. | $92.65 | 2019 | |
| United Therapeutics Corporation | $91.72 | 2019 | |
| Grifols USA, LLC | $85.95 | 2019-2020 | |
| Boston Scientific Corporation | $81.75 | 2022-2023 | Watchman |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.09 | 2020-2023 | Xarelto |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $53.61 | 2019-2020 | |
| Cook Incorporated | $32.43 | 2024 | |
| Ethicon INC. | $22.27 | 2025 | Monarch Platform |
| Shionogi INC | $19.88 | 2025 | Fetroja |
| Chiesi USA, INC. | $19.60 | 2022 | |
| Olympus America INC. | $19.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2020 | |
| Pfizer INC. | $15.19 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $13.27 | 2020 | |
| Advanced Respiratory, INC | $11.72 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.44 | 2024 | Lifevest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.